Reactive management of stomatitis induced by multikinase inhibitor treatment
General recommendation: Stomatitis can significantly impair quality of life. Comprehensive oral care, aggressive pain management and adequate nutritional support are key considerations.1, 2
Treatment overview
Stomatitis associated with targeted therapies includes a range of subjective and objective symptoms and may differ from the oral mucositis associated with traditional chemotherapy.2
Use of sodium-containing mouthwashes is recommended and the frequency can be increase to hourly if needed.2 Symptomatic relief may be obtained using a mouthwash consisting of equal parts of 2% viscous lidocaine, diphenhydramine, and bismuth subsalicylate or aluminium/magnesium hydroxide, or alternative mouthwashes.3-6 If the patient finds mouthwash use painful, pain medication may be taken first (e.g. viscous lidocaine 2%). 2,6 Aggressive pain relief should be administered, including opioids for persistent severe pain.1, 2
More effective approaches to preventing and treating stomatitis are needed.1 A Cochrane review of randomised controlled trials identified 10 interventions with some efficacy in either preventing or reducing the severity of oral mucositis during cancer treatment: aloe vera, amifostine, cryotherapy (ice chips), granulocyte-colony stimulating factor (G-CSF), intravenous glutamine, honey, keratinocyte growth factor, laser, polymyxin/tobramycin/amphotericin (PTA) antibiotic pastille/paste and sucralfate.7
Patients should be evaluated weekly. With the second or third occurrence of stomatitis intensifying supportive measures is advised. If symptoms worsen despite the intensified measures, drug interruption or discontinuation should be considered.
Table 35: Management of stomatitis associated with multikinase inhibitors, by CTCAE grade grade2-6
Grade |
Description |
---|---|
1 |
|
2 |
|
3 |
|
4 |
|
Products
- Viscous lidocaine 2%
- Topical NSAID (e.g. benzocaine)
- Opioid analgesic
Multikinase inhibitor treatment
Continue with/withhold the selected multikinase inhibitor treatment regimen, as recommended in the current and relevant SPC and according to the patient’s condition.
References
- Lacouture ME, et al. MASCC Skin Toxicity Study Group. Support Care Cancer. 2011; 19: 1079-95.
- Boers-Doets CB. The TARGET SYSTEM. Approach to assessment, grading, and management of dermatological & mucosal side effects of targeted anticancer therapies. ISBN 978-94-92070-00-5. 2014.
- Kollmannsberger C, et al. Oncologist. 2011; 16: 543-53.
- De Wit M, et al. Support Care Cancer. 2014; 22: 837-46.
- Brose MS, et al. Cancer Treatment Reviews. 2018; 66:64–73.
- Krishnamoorthy SK, et al. Therap Adv Gastroenterol. 2015;8:285-97.
- Worthington HV, et al. Cochrane Database Syst Rev. 2011 Apr 13;(4): CD00097.